Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Dow
Medtronic
McKesson
Mallinckrodt
Harvard Business School
Express Scripts

Last Updated: November 18, 2019

DrugPatentWatch Database Preview

Abaloparatide - Generic Drug Details

See Plans and Pricing

« Back to Dashboard

What are the generic drug sources for abaloparatide and what is the scope of patent protection?

Abaloparatide is the generic ingredient in one branded drug marketed by Radius Health Inc and is included in one NDA. There are three patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Abaloparatide has thirty-four patent family members in twenty-four countries.

One supplier is listed for this compound.

Summary for abaloparatide
International Patents:34
US Patents:3
Tradenames:1
Applicants:1
NDAs:1
Suppliers / Packagers: 1
Bulk Api Vendors: 3
Clinical Trials: 9
Drug Prices: Drug price trends for abaloparatide
DailyMed Link:abaloparatide at DailyMed
Drug Prices for abaloparatide

See drug prices for abaloparatide

Recent Clinical Trials for abaloparatide

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Hospital for Special Surgery, New YorkPhase 2
University of RochesterPhase 1
Johns Hopkins UniversityPhase 2

See all abaloparatide clinical trials

Pharmacology for abaloparatide
Synonyms for abaloparatide
247062-33-5
Abaloparatide [USAN:INN]
Abaloparatide-SC
BA058
BIM-44058
C2.29-methyl(22-L-glutamic acid(F>E),23-L-leucine(F>L),25-L-glutamic acid(H>E),26-L-lysine(H>K),28-L-leucine(I>L),30-L-lysine(E>K),31-L-leucine(I>L))human parathyroid hormone-related protein-(1-34)-proteinamide
Tymlos

US Patents and Regulatory Information for abaloparatide

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Radius Health Inc TYMLOS abaloparatide SOLUTION;SUBCUTANEOUS 208743-001 Apr 28, 2017 RX Yes Yes   Start Trial   Start Trial   Start Trial
Radius Health Inc TYMLOS abaloparatide SOLUTION;SUBCUTANEOUS 208743-001 Apr 28, 2017 RX Yes Yes   Start Trial   Start Trial   Start Trial
Radius Health Inc TYMLOS abaloparatide SOLUTION;SUBCUTANEOUS 208743-001 Apr 28, 2017 RX Yes Yes   Start Trial   Start Trial   Start Trial
Radius Health Inc TYMLOS abaloparatide SOLUTION;SUBCUTANEOUS 208743-001 Apr 28, 2017 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Merck
Medtronic
Boehringer Ingelheim
Johnson and Johnson
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.